Moliya
Moliya
Bosh sahifaABBV • NYSE
AbbVie
218,34 $
Seans yopilganidan keyin:
218,55 $
(0,096%)+0,21
Yopilgan:12-sen, 19:13:21 (GMT-4) · USD · NYSE · Ogohlantirish
AksiyalarAQSH qimmatli qogʻoziBosh shtabi: AQSH
Yopilish kursi
220,22 $
Kunlik diapazon
218,23 $ - 220,38 $
Yillik diapazon
163,81 $ - 221,77 $
Bozor kapitalizatsiyasi
385,71 mlrd USD
Oʻrtacha hajm
4,80 mln
Narx/foyda
103,91
Dividend daromadliligi
3,00%
Asosiy maydon
NYSE
Moliyaviy axborot
Moliyaviy hisobot
Daromad
Sof foyda
(USD)iyn, 2025Y/Y qiyosi
Daromad
15,42 mlrd6,65%
Joriy xarajat
5,29 mlrd0,53%
Sof foyda
938,00 mln-31,53%
Sof foyda marjasi
6,08-35,80%
Har bir ulushga tushum
2,9712,08%
EBITDA
7,84 mlrd9,93%
Amaldagi soliq stavkasi
39,45%
Jami aktivlari
Jami passivlari
(USD)iyn, 2025Y/Y qiyosi
Naqd pul va qisqa investitsiyalar
6,47 mlrd-50,85%
Jami aktivlari
137,18 mlrd-3,35%
Jami passivlari
137,32 mlrd1,63%
Umumiy kapital
-138,00 mln
Tarqatilgan aksiyalar
1,77 mlrd
Narxi/balansdagi bahosi
-2,20 ming
Aktivlardan daromad
10,59%
Kapitaldan daromad
20,39%
Naqd pulning sof oʻzgarishi
(USD)iyn, 2025Y/Y qiyosi
Sof foyda
938,00 mln-31,53%
Operatsiyalardan naqd pul
5,15 mlrd126,90%
Sarmoyadan naqd pul
-1,18 mlrd-7,17%
Moliyadan naqd pul
-2,71 mlrd55,55%
Naqd pulning sof oʻzgarishi
1,29 mlrd126,17%
Boʻsh pul
6,02 mlrd105,93%
Haqida
AbbVie Inc. is an American pharmaceutical company headquartered in North Chicago, Illinois. Its major products are: Humira, approved to treat autoimmune diseases including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, plaque psoriasis, crohn's disease and ulcerative colitis and administered via injection; Skyrizi, an interleukin-23 inhibitor also used to treat autoimmune diseases; Rinvoq, used to treat arthritis; and Botox. Its other major products include Imbruvica to treat cancer, Vraylar to treat schizophrenia and bipolar disorder, Venclexta to treat leukemia and lymphoma, Mavyret to treat Hepatitis C, and Epkinly, a blood-cancer therapy developed in partnership with Genmab. The company is also committed to product development for other treatments of cancer, neurologic diseases, eye care, and cystic fibrosis. The company's pipeline also includes drug candidates for Parkinson's disease including Vyalev and tavapadon. The company is ranked sixth on the list of largest biomedical companies by revenue. It is ranked 77th on the Fortune 500 and 108th on the Forbes Global 2000. Wikipedia
Tashkil etilgan
10-apr, 2012
Xodimlar soni
55 000
Yana
Bu sizni qiziqtirishi mumkin
Bu roʻyxat oxirgi qidiruvlar, kuzatilgan aksiyalar va boshqa faoliyatdan tuzilgan. Batafsil

Barcha axborotlar faqat maʼlumot sifatida “shundayligicha” taqdim etilgan, ulardan moliyaviy maslahat sifatida foydalanmang, ular savdo maqsadlari yoki investitsiya, soliq, yuridik, buxgalteriya yoki boshqa turdagi maslahat emas. Google investitsiya borasida maslahatchi emas, bu roʻyxatdagi kompaniyalar yoki ularning aksiyalari borasida hech qanday nuqtai nazar, tavsiya yoki fikr bildirmaydi. Har qanday savdoni boshlashdan oldin broker yoki moliyaviy vakil bilan maslahatlashib, narxlarni tekshiring. Batafsil
Aloqador qidiruvlar
Qidiruv
Qidiruv maydonini tozalash
Qidiruvni yopish
Google ilovalari
Asosiy menyu